ViGenCell’s Immune Cell Therapies To Get A Boost From $85M IPO

IPO Priced At Top Of Stock Price Band

 
• By Jung Won Shin
  
human cells and veins
ViGenCell Developing Both Autologous And Universal Cell Therapies • Source: Alamy
Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

SpotifyApple PodcastsWebsite

More from South Korea

More from Focus On Asia